{"id":"basiliximab-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201439","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Basiliximab binds specifically to the alpha chain (CD25) of the IL-2 receptor on activated T lymphocytes. By blocking IL-2 signaling, it inhibits T cell proliferation and differentiation, thereby suppressing the immune response responsible for organ rejection. This selective targeting of activated T cells makes it useful as an induction immunosuppressant in transplantation.","oneSentence":"Basiliximab is a chimeric monoclonal antibody that blocks the interleukin-2 (IL-2) receptor on T cells, preventing T cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:28.521Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in adult and pediatric patients receiving renal transplants (as part of an immunosuppressive regimen)"}]},"trialDetails":[{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT02377193","phase":"PHASE4","title":"Simulect Versus ATG in Sensitized Renal Transplant Patient","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2013-09","conditions":"Renal Transplant Rejection","enrollment":60},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":"Myeloma","enrollment":30},{"nctId":"NCT06374095","phase":"","title":"1 vs 7 RATG Infusions in Renal Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2024-07-30","conditions":"Kidney Replacement","enrollment":75},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT05139004","phase":"PHASE1","title":"90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-07-19","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":7},{"nctId":"NCT02342145","phase":"PHASE4","title":"Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major","status":"COMPLETED","sponsor":"Zhongming Zhang","startDate":"2015-04","conditions":"Beta-Thalassemia Major, Graft-versus-host Disease (GVHD)","enrollment":205},{"nctId":"NCT04736381","phase":"","title":"Impact of the Microbiota on the Likelihood of Renal Graft Rejection","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2021-10-07","conditions":"Kidney Transplant Rejection","enrollment":70},{"nctId":"NCT01476839","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-11-09","conditions":"Recurrent Adult Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT02342782","phase":"PHASE1","title":"Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-06-08","conditions":"Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03478215","phase":"PHASE2","title":"Mesenchymal Stromal Cells in Living Donor Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2016-12","conditions":"Renal Transplantation, Mesenchymal Stem Cells","enrollment":24},{"nctId":"NCT03031470","phase":"PHASE2","title":"Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation","status":"TERMINATED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2015-03-10","conditions":"Ischemia-reperfusion Injury in Liver Transplant, Early Allograft Dysfunction","enrollment":40},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT00933231","phase":"PHASE3","title":"Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-08-17","conditions":"Kidney Transplantation","enrollment":281},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT06196996","phase":"NA","title":"Allogeneic Regenerative Islet Transplantation for the Treatment of Brittle Type 1 Diabetes Mellitus","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2021-09-14","conditions":"Brittle Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02464878","phase":"PHASE2","title":"Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Kidney Transplant, Type 1 Diabetes","enrollment":2},{"nctId":"NCT00752479","phase":"PHASE1, PHASE2","title":"Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2008-05","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT06087003","phase":"","title":"Pediatric Induction Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Gang Chen","startDate":"2013-03-03","conditions":"Kidney Transplant Rejection, Pediatric Kidney Disease","enrollment":958},{"nctId":"NCT06066840","phase":"PHASE4","title":"Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-08-01","conditions":"Safety and Efficacy","enrollment":45},{"nctId":"NCT02409147","phase":"NA","title":"Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2016-01","conditions":"Uterus Transplant","enrollment":""},{"nctId":"NCT02366728","phase":"PHASE2","title":"DC Migration Study for Newly-Diagnosed GBM","status":"COMPLETED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2015-10-12","conditions":"Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma","enrollment":64},{"nctId":"NCT04738981","phase":"PHASE3","title":"Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2021-02-01","conditions":"Graft Vs Host Disease","enrollment":130},{"nctId":"NCT05294822","phase":"NA","title":"Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-09-30","conditions":"Diabetes","enrollment":20},{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT05021276","phase":"PHASE4","title":"Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-12-15","conditions":"Safety and Efficacy","enrollment":50},{"nctId":"NCT05013034","phase":"PHASE2","title":"Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients","status":"UNKNOWN","sponsor":"Fort Worth Clinical Sciences Working Group","startDate":"2021-10-15","conditions":"SARS-CoV-2 Acute Respiratory Disease, SARS-CoV2 Infection, Cytokine Storm","enrollment":300},{"nctId":"NCT00566813","phase":"PHASE1, PHASE2","title":"Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2004-11","conditions":"Diabetes Mellitus, Type 1","enrollment":10},{"nctId":"NCT00626483","phase":"PHASE1","title":"Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia","status":"COMPLETED","sponsor":"Gary Archer Ph.D.","startDate":"2007-04-24","conditions":"Malignant Neoplasms Brain","enrollment":34},{"nctId":"NCT02523768","phase":"PHASE4","title":"Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2011-01-08","conditions":"Glomerulonephritis, IgAN","enrollment":117},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT01856257","phase":"PHASE2","title":"Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-07","conditions":"Primary Renal Allograft Candidate, Kidney Transplantation","enrollment":71},{"nctId":"NCT01387659","phase":"NA","title":"Evaluate Tolerability of Myfortic®/Simulect® and Tacrolimus Without Steroids in Three Patient Populations","status":"TERMINATED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2011-03","conditions":"Diabetes, Immunosuppression","enrollment":2},{"nctId":"NCT04337593","phase":"PHASE2","title":"Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL","status":"UNKNOWN","sponsor":"Beijing Tongren Hospital","startDate":"2020-06-01","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":20},{"nctId":"NCT01120028","phase":"PHASE2, PHASE3","title":"Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2010-09","conditions":"Kidney Transplantation","enrollment":852},{"nctId":"NCT01453218","phase":"PHASE3","title":"Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction","status":"COMPLETED","sponsor":"Hospital Vall d'Hebron","startDate":"2011-10","conditions":"Renal Insufficiency","enrollment":30},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT03006419","phase":"PHASE4","title":"Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2016-12-01","conditions":"Kidney Transplant Rejection, Kidney Transplant; Complications","enrollment":100},{"nctId":"NCT01136395","phase":"PHASE2","title":"Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2010-01","conditions":"Kidney Transplantation, Rituximab (RTx), Living Donors","enrollment":85},{"nctId":"NCT00434811","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT01649427","phase":"PHASE4","title":"Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10-17","conditions":"Pharmacokinetics Study in de Novo Kidney Transplantation","enrollment":73},{"nctId":"NCT01485055","phase":"PHASE2","title":"Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease","status":"TERMINATED","sponsor":"Nationwide Children's Hospital","startDate":"2011-12","conditions":"Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease","enrollment":11},{"nctId":"NCT01541176","phase":"PHASE4","title":"Absence of Steroid in Renal Transplantation and Digital Fibrosis Observation","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-04","conditions":"Renal Transplant","enrollment":193},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT02328963","phase":"PHASE4","title":"Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-05-02","conditions":"Transplantation Infection, Cytomegalovirus Infection","enrollment":186},{"nctId":"NCT02957552","phase":"PHASE1","title":"Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation","status":"UNKNOWN","sponsor":"University Hospital Tuebingen","startDate":"2017-03-10","conditions":"Pediatric Liver Transplantation","enrollment":7},{"nctId":"NCT00154284","phase":"PHASE3","title":"Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Organ Transplantation, Renal Transplantation","enrollment":114},{"nctId":"NCT01842139","phase":"PHASE1","title":"Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-12-05","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":7},{"nctId":"NCT00888628","phase":"PHASE1, PHASE2","title":"Study of Islet Transplantation in Type 1 Diabetic Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-05","conditions":"Diabetes Mellitus, Type I","enrollment":7},{"nctId":"NCT02056938","phase":"PHASE4","title":"ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2014-06","conditions":"Kidney Transplantation","enrollment":19},{"nctId":"NCT01884571","phase":"PHASE2","title":"Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-10","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":31},{"nctId":"NCT00468117","phase":"PHASE3","title":"Efficacy of Islet After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT03192657","phase":"PHASE2","title":"Basiliximab Treating Interstitial Pneumonia of CADM","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-07","conditions":"Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis","enrollment":100},{"nctId":"NCT00284947","phase":"PHASE4","title":"Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-01","conditions":"Kidney Transplantation, Adverse Effects","enrollment":7},{"nctId":"NCT00369161","phase":"PHASE4","title":"A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-06","conditions":"Renal Transplantation","enrollment":228},{"nctId":"NCT00229138","phase":"PHASE4","title":"Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Kidney Transplantation","enrollment":291},{"nctId":"NCT02843841","phase":"NA","title":"Polyclonal Antilymphocyte Globulin (ATG) & Intestinal Immune Barrier After Kidney Transplantation","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2014-12","conditions":"Disorder Related to Renal Transplantation","enrollment":63},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT03005236","phase":"PHASE4","title":"AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation","status":"UNKNOWN","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2017-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT02894606","phase":"","title":"Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients","status":"UNKNOWN","sponsor":"University Hospital, Brest","startDate":"2015-02","conditions":"Renal Transplant","enrollment":40},{"nctId":"NCT02770430","phase":"PHASE2","title":"Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2015-09","conditions":"Graft vs Host Disease","enrollment":90},{"nctId":"NCT01625377","phase":"PHASE3","title":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Liver Transplantation","enrollment":188},{"nctId":"NCT00464555","phase":"PHASE2","title":"Strategies to Improve Islet Survival","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-12","conditions":"Type 1 Diabetes Mellitus","enrollment":5},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""},{"nctId":"NCT00468403","phase":"PHASE2","title":"LEA29Y (Belatacept) Emory Edmonton Protocol","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-10","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT00434850","phase":"PHASE2","title":"Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 1","enrollment":14},{"nctId":"NCT01656135","phase":"PHASE4","title":"Reference Group Trial for The ONE Study","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2012-12","conditions":"End-stage Renal Failure, Kidney Graft Rejection","enrollment":70},{"nctId":"NCT00975975","phase":"PHASE2","title":"Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2009-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":17},{"nctId":"NCT02683291","phase":"PHASE4","title":"Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients","status":"COMPLETED","sponsor":"Associação Médico Espírita de Botucatu","startDate":"2014-01","conditions":"Disorder Related to Renal Transplantation, Cytomegalovirus Infections","enrollment":48},{"nctId":"NCT00626015","phase":"PHASE1","title":"Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"John Sampson","startDate":"2007-03","conditions":"Malignant Neoplasms of Brain","enrollment":16},{"nctId":"NCT02561767","phase":"PHASE1, PHASE2","title":"Effect of BM-MSCs in DCD Kidney Transplantation","status":"UNKNOWN","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-10","conditions":"Kidney Transplantation, Acute Kidney Tubular Necrosis","enrollment":120},{"nctId":"NCT02492490","phase":"PHASE1, PHASE2","title":"Effect of SVF Derived MSC in DCD Renal Transplantation","status":"UNKNOWN","sponsor":"Fuzhou General Hospital","startDate":"2014-12","conditions":"Uremia","enrollment":120},{"nctId":"NCT02459977","phase":"NA","title":"The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2012-04","conditions":"Kidney Transplantation","enrollment":40},{"nctId":"NCT01354301","phase":"PHASE4","title":"Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate","status":"COMPLETED","sponsor":"Hospital do Rim e Hipertensão","startDate":"2011-05","conditions":"Cytomegalovirus Infection, Renal Transplant Failure, Transplant; Complication, Rejection","enrollment":300},{"nctId":"NCT00235300","phase":"PHASE2","title":"An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2000-05","conditions":"Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy","enrollment":240},{"nctId":"NCT00928811","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant","status":"TERMINATED","sponsor":"Drexel University College of Medicine","startDate":"2009-05","conditions":"End Stage Renal Disease","enrollment":5},{"nctId":"NCT00378014","phase":"PHASE3","title":"Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-08","conditions":"Liver Transplantation","enrollment":276},{"nctId":"NCT02328222","phase":"PHASE4","title":"ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION","status":"COMPLETED","sponsor":"Unidad de Investigacion Medica en Enfermedades Renales","startDate":"2010-06","conditions":"END STAGE RENAL DISEASE","enrollment":71},{"nctId":"NCT00604357","phase":"PHASE3","title":"CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2008-12","conditions":"End Stage Liver Disease, Impaired Renal Function","enrollment":27},{"nctId":"NCT00724022","phase":"PHASE4","title":"Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital Freiburg","startDate":"2008-06","conditions":"Disorder Related to Renal Transplantation","enrollment":600},{"nctId":"NCT00965094","phase":"PHASE4","title":"Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-12","conditions":"Chronic Renal Failure","enrollment":36},{"nctId":"NCT00634920","phase":"PHASE4","title":"Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Function","enrollment":204},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00956293","phase":"PHASE4","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Renal Transplantation","enrollment":207},{"nctId":"NCT01079143","phase":"PHASE3","title":"Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Renal Interstitial Fibrosis","enrollment":194},{"nctId":"NCT00853424","phase":"PHASE3","title":"A Comparison of Islet Cell Transplantation With Medical Therapy for the Treatment of Diabetic Eye Disease","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2009-12","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00658320","phase":"PHASE3","title":"Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Kidney Transplantation","enrollment":122},{"nctId":"NCT00137345","phase":"PHASE3","title":"Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-06","conditions":"Kidney Transplant","enrollment":500},{"nctId":"NCT00296244","phase":"PHASE4","title":"Steroid Free Immunosuppression in Liver Transplantation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2006-02","conditions":"Liver Cirrhosis, Liver Transplant Disorder","enrollment":40},{"nctId":"NCT00284921","phase":"PHASE3","title":"MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-04","conditions":"De Novo Kidney Transplant","enrollment":60},{"nctId":"NCT00531440","phase":"PHASE3","title":"This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2001-11","conditions":"Renal Transplantation","enrollment":256},{"nctId":"NCT00610961","phase":"","title":"Induction Related BK Viremia in Renal Transplant Patients","status":"COMPLETED","sponsor":"University of Florida","startDate":"2007-10","conditions":"Disease Due to BK Polyomavirus, Transplantation Infection, Disorder Related to Transplantation","enrollment":60},{"nctId":"NCT00149890","phase":"PHASE3","title":"Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-03","conditions":"Liver Transplantation, Infection","enrollment":77}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Basiliximab treatment","genericName":"Basiliximab treatment","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Basiliximab is used to treat conditions such as kidney transplantation and various types of leukemia, including acute myelogenous leukemia, acute lymphocytic leukemia, and chronic myelogenous leukemia. It is administered as part of an immunosuppressive regimen, often in combination with other treatments like belatacept, anti-thymocyte globulin, and methylprednisolone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}